Journal: United European gastroenterology journal
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, primarily treated with chemotherapy.
Current regimens, such as FOLFIRINOX and gemcitabine combinations, are chosen empirically without biomarker guidance.
Emerging predictive transcriptomic signatures offer practical tools to personalize therapy by identifying patients likely to benefit from specific drugs, enabling treatment optimization and de-escalation. These signatures include:
- GemPred
- GemCore
- Pancreas-View
These signatures have been retrospectively validated in large cohorts and clinical trials. They show a correlation between predicted drug sensitivity and improved survival.
Ongoing prospective studies aim to confirm their clinical utility, advancing transcriptomic profiling as a means to achieve precision chemotherapy in PDAC.